Reported results
- Worldwide net sales were $763.7 million, a decrease of 0.7%, or a decrease of 0.5% on a constant currency basis.
- Base business sales (non-GAAP), excluding Nevro, were $690.0 million, an increase of 3.0%, as reported.
- GAAP net income for the quarter was $141.2 million.
- GAAP diluted earnings per share was $1.04, an increase of 18.2%, while non-GAAP diluted EPS was $1.23, an increase of 4.4%.
- GAAP gross profit as a percentage of net sales was 66.7%, and non-GAAP adjusted Gross Profit as a percentage of sales was 69.5%.
Guidance
- Full-year 2026 revenue of $3.09 billion, representing 5.1% revenue growth as compared to fiscal 2025.
- Full-year fiscal 2026 non-GAAP fully diluted EPS in the range of $4.95 to $5.05, representing 24.4% to 26.9% growth over fiscal 2025 non-GAAP fully diluted EPS.
Price and volatility reaction
The stock moved -12.8% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -18.4 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 81.44 | 2026-11-05 |
| Close after release | 71.05 | 2026-11-06 |
| Realised move | -12.8% | close to close |
| 30d ATM IV change | -18.4 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
